AustralieFrV1, PascalFrancis, Curation, bibRecord, 005244

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

Identifieur interne : 005244 ( PascalFrancis/Curation ); précédent : 005243; suivant : 005245

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

Auteurs : Madeleine Duvic [États-Unis] ; Reinhard Dummer [Suisse] ; Jürgen C. Becker [Autriche] ; Nicolas Poulalhon [France] ; Pablo Ortiz Romero [Espagne] ; Maria Grazia Bernengo [Italie] ; Celeste Lebbe [France] ; Chalid Assaf [Allemagne] ; Margaret Squier [États-Unis] ; Denise Williams [États-Unis] ; Miriam Marshood [États-Unis] ; FENG TAI [États-Unis] ; H. Miles Prince [Australie]

Source :

European journal of cancer : (1990) [ 0959-8049 ] ; 2013.

RBID : Pascal:13-0084490

Descripteurs français

Pascal (Inist)
- Panobinostat, Activité biologique, Bexarotène, Mycosis fongoïde, Homme, Résistance traitement, Essai clinique phase II, Cancérologie, Syndrome de Sezary, Anticancéreux, Chronique, Lymphome T cutané, Hémopathie maligne lymphoïde, Hémopathie lymphoïde T.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antineoplastic agent, Bexarotene, Biological activity, Cancerology, Chronic, Cutaneous T cell lymphoma, Human, Lymphoid neoplasm, Mycosis fungoides, Panobinostat, Phase II trial, Sezary syndrome, T cell neoplasm, Treatment resistance.

Abstract

Background: Panobinostat is a potent, oral pan-deacetylase inhibitor (pan-DACi) that increases the acetylation of proteins involved in multiple oncogenic pathways. Here, panobinostat is studied in bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma (CTCL). Patients and methods: Patients with CTCL subtypes mycosis fungoides and Sézary syndrome who received ≥2 prior systemic therapy regimens received panobinostat (20 mg) three times every week. The primary objective was overall response rate (ORR) as determined by a combined evaluation of skin disease and involvement of lymph node and viscera. Disease progression was defined as an unconfirmed, ≥25% increase in modified Severity Weighted Assessment Tool (mSWAT) compared with nadir. Results: Seventy-nine bexarotene-exposed and 60 bexarotene-naïve patients were enrolled. Reductions in baseline mSWAT scores were observed in 103 patients (74.1%). The ORR was 17.3%) in all patients in the primary analysis (15.2% and 20.0% in the bexarotene-exposed and -naive groups, respectively). The median progression-free survival was 4.2 and 3.7 months in the bexarotene-exposed and -naive groups, respectively. The median duration of response was 5.6 months in the bexarotene-exposed patients and was not reached at data cutoff in the bexarotene-naive patients. Additional responses were observed when less-stringent progression criteria were used. The most common adverse events were thrombocytopenia, diarrhoea, fatigue and nausea. Thrombocytopenia and neutropenia were the only grade 3/4 adverse events in >5% of patients and were manageable. Conclusion: Despite a very conservative definition of disease progression, panobinostat demonstrated activity with a manageable safety profile in bexarotene-exposed and -naïve CTCL patients. ClinicalTrials.gov Identifier: NCT00425555.

A01	`01`	`1`		`@0 0959-8049`
A03		`1`		`@0 Eur. j. cancer : (1990)`
A05				`@2 49`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial`
A11	`01`	`1`		`@1 DUVIC (Madeleine)`
A11	`02`	`1`		`@1 DUMMER (Reinhard)`
A11	`03`	`1`		`@1 BECKER (Jürgen C.)`
A11	`04`	`1`		`@1 POULALHON (Nicolas)`
A11	`05`	`1`		`@1 ORTIZ ROMERO (Pablo)`
A11	`06`	`1`		`@1 GRAZIA BERNENGO (Maria)`
A11	`07`	`1`		`@1 LEBBE (Celeste)`
A11	`08`	`1`		`@1 ASSAF (Chalid)`
A11	`09`	`1`		`@1 SQUIER (Margaret)`
A11	`10`	`1`		`@1 WILLIAMS (Denise)`
A11	`11`	`1`		`@1 MARSHOOD (Miriam)`
A11	`12`	`1`		`@1 FENG TAI`
A11	`13`	`1`		`@1 PRINCE (H. Miles)`
A14	`01`			`@1 MD Anderson Cancer Center @2 Houston, TX @3 USA @Z 1 aut.`
A14	`02`			`@1 University Hospital Zurich, Department of Dermatology @2 Zurich @3 CHE @Z 2 aut.`
A14	`03`			`@1 Medical University of Graz @2 Graz @3 AUT @Z 3 aut.`
A14	`04`			`@1 Centre Hospitalier Lyon Sud @2 Pierre-Bénite @3 FRA @Z 4 aut.`
A14	`05`			`@1 Instituto i+12 del Hospital 12 de Octubre, Facultad de Medicina, Universidad Complutense @2 Madrid @3 ESP @Z 5 aut.`
A14	`06`			`@1 University of Turin, Department of Biomedical Science and Human Oncology @2 Turin @3 ITA @Z 6 aut.`
A14	`07`			`@1 AP-HP Hôpital Saint-Louis, Department of Dermatology and Center of Clinical Investigation, Université Paris Diderot @2 Paris @3 FRA @Z 7 aut.`
A14	`08`			`@1 HELIOS Klinikum Krefeld, Department of Dermatology @2 Krefeld @3 DEU @Z 8 aut.`
A14	`09`			`@1 Skin Cancer Center Charité, Department of Dermatology and Allergology, Charité-Universitätsmedizin Berlin @2 Berlin @3 DEU @Z 8 aut.`
A14	`10`			`@1 Novartis Pharmaceuticals Corporation @2 East Hanover, NJ @3 USA @Z 9 aut. @Z 10 aut. @Z 11 aut. @Z 12 aut.`
A14	`11`			`@1 Peter MacCallum Cancer Centre and University of Melbourne @2 Melbourne @3 AUS @Z 13 aut.`
A20				`@1 386-394`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 12648 @5 354000182501500140`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 33 ref.`
A47	`01`	`1`		`@0 13-0084490`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 European journal of cancer : (1990)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background: Panobinostat is a potent, oral pan-deacetylase inhibitor (pan-DACi) that increases the acetylation of proteins involved in multiple oncogenic pathways. Here, panobinostat is studied in bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma (CTCL). Patients and methods: Patients with CTCL subtypes mycosis fungoides and Sézary syndrome who received ≥2 prior systemic therapy regimens received panobinostat (20 mg) three times every week. The primary objective was overall response rate (ORR) as determined by a combined evaluation of skin disease and involvement of lymph node and viscera. Disease progression was defined as an unconfirmed, ≥25% increase in modified Severity Weighted Assessment Tool (mSWAT) compared with nadir. Results: Seventy-nine bexarotene-exposed and 60 bexarotene-naïve patients were enrolled. Reductions in baseline mSWAT scores were observed in 103 patients (74.1%). The ORR was 17.3%) in all patients in the primary analysis (15.2% and 20.0% in the bexarotene-exposed and -naive groups, respectively). The median progression-free survival was 4.2 and 3.7 months in the bexarotene-exposed and -naive groups, respectively. The median duration of response was 5.6 months in the bexarotene-exposed patients and was not reached at data cutoff in the bexarotene-naive patients. Additional responses were observed when less-stringent progression criteria were used. The most common adverse events were thrombocytopenia, diarrhoea, fatigue and nausea. Thrombocytopenia and neutropenia were the only grade 3/4 adverse events in >5% of patients and were manageable. Conclusion: Despite a very conservative definition of disease progression, panobinostat demonstrated activity with a manageable safety profile in bexarotene-exposed and -naïve CTCL patients. ClinicalTrials.gov Identifier: NCT00425555.
C02	`01`	`X`		`@0 002B02`
C02	`02`	`X`		`@0 002B04`
C03	`01`	`X`	`FRE`	`@0 Panobinostat @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Panobinostat @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Panobinostat @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Activité biologique @5 02`
C03	`02`	`X`	`ENG`	`@0 Biological activity @5 02`
C03	`02`	`X`	`SPA`	`@0 Actividad biológica @5 02`
C03	`03`	`X`	`FRE`	`@0 Bexarotène @2 NK @2 FR @5 03`
C03	`03`	`X`	`ENG`	`@0 Bexarotene @2 NK @2 FR @5 03`
C03	`03`	`X`	`SPA`	`@0 Bexaroteno @2 NK @2 FR @5 03`
C03	`04`	`X`	`FRE`	`@0 Mycosis fongoïde @5 04`
C03	`04`	`X`	`ENG`	`@0 Mycosis fungoides @5 04`
C03	`04`	`X`	`SPA`	`@0 Micosis fungoides @5 04`
C03	`05`	`X`	`FRE`	`@0 Homme @5 05`
C03	`05`	`X`	`ENG`	`@0 Human @5 05`
C03	`05`	`X`	`SPA`	`@0 Hombre @5 05`
C03	`06`	`X`	`FRE`	`@0 Résistance traitement @5 06`
C03	`06`	`X`	`ENG`	`@0 Treatment resistance @5 06`
C03	`06`	`X`	`SPA`	`@0 Resistencia tratamiento @5 06`
C03	`07`	`X`	`FRE`	`@0 Essai clinique phase II @5 07`
C03	`07`	`X`	`ENG`	`@0 Phase II trial @5 07`
C03	`07`	`X`	`SPA`	`@0 Ensayo clínico fase II @5 07`
C03	`08`	`X`	`FRE`	`@0 Cancérologie @5 08`
C03	`08`	`X`	`ENG`	`@0 Cancerology @5 08`
C03	`08`	`X`	`SPA`	`@0 Cancerología @5 08`
C03	`09`	`X`	`FRE`	`@0 Syndrome de Sezary @5 10`
C03	`09`	`X`	`ENG`	`@0 Sezary syndrome @5 10`
C03	`09`	`X`	`SPA`	`@0 Sezary síndrome @5 10`
C03	`10`	`X`	`FRE`	`@0 Anticancéreux @5 25`
C03	`10`	`X`	`ENG`	`@0 Antineoplastic agent @5 25`
C03	`10`	`X`	`SPA`	`@0 Anticanceroso @5 25`
C03	`11`	`X`	`FRE`	`@0 Chronique @5 26`
C03	`11`	`X`	`ENG`	`@0 Chronic @5 26`
C03	`11`	`X`	`SPA`	`@0 Crónico @5 26`
C03	`12`	`X`	`FRE`	`@0 Lymphome T cutané @4 CD @5 96`
C03	`12`	`X`	`ENG`	`@0 Cutaneous T cell lymphoma @4 CD @5 96`
C03	`12`	`X`	`SPA`	`@0 Linfoma T cutáneo @4 CD @5 96`
C03	`13`	`X`	`FRE`	`@0 Hémopathie maligne lymphoïde @4 CD @5 97`
C03	`13`	`X`	`ENG`	`@0 Lymphoid neoplasm @4 CD @5 97`
C03	`14`	`X`	`FRE`	`@0 Hémopathie lymphoïde T @4 CD @5 98`
C03	`14`	`X`	`ENG`	`@0 T cell neoplasm @4 CD @5 98`
C07	`01`	`X`	`FRE`	`@0 Inhibiteur histone deacetylase @5 37`
C07	`01`	`X`	`ENG`	`@0 Histone deacetylase inhibitor @5 37`
C07	`01`	`X`	`SPA`	`@0 Inhibidor histone deacetylase @5 37`
C07	`02`	`X`	`FRE`	`@0 Hémopathie maligne @2 NM @5 38`
C07	`02`	`X`	`ENG`	`@0 Malignant hemopathy @2 NM @5 38`
C07	`02`	`X`	`SPA`	`@0 Hemopatía maligna @2 NM @5 38`
C07	`03`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`03`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`03`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`04`	`X`	`FRE`	`@0 Lymphome non hodgkinien @5 39`
C07	`04`	`X`	`ENG`	`@0 Non Hodgkin lymphoma @5 39`
C07	`04`	`X`	`SPA`	`@0 Linfoma no Hodgkin @5 39`
C07	`05`	`X`	`FRE`	`@0 Syndrome lymphoprolifératif @2 NM @5 40`
C07	`05`	`X`	`ENG`	`@0 Lymphoproliferative syndrome @2 NM @5 40`
C07	`05`	`X`	`SPA`	`@0 Linfoproliferativo síndrome @2 NM @5 40`
C07	`06`	`X`	`FRE`	`@0 Pathologie de la peau @5 41`
C07	`06`	`X`	`ENG`	`@0 Skin disease @5 41`
C07	`06`	`X`	`SPA`	`@0 Piel patología @5 41`
C07	`07`	`X`	`FRE`	`@0 Hématodermie @5 42`
C07	`07`	`X`	`ENG`	`@0 Cutaneous hematologic disease @5 42`
C07	`07`	`X`	`SPA`	`@0 Hematodermia @5 42`
C07	`08`	`X`	`FRE`	`@0 Lymphome périphérique à cellules T @5 43`
C07	`08`	`X`	`ENG`	`@0 Peripheral T cell lymphoma @5 43`
C07	`08`	`X`	`SPA`	`@0 Linfoma célula T periférica @5 43`
N21				`@1 056`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C21

Links to Exploration step

Pascal:13-0084490

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial</title>
<author><name sortKey="Duvic, Madeleine" sort="Duvic, Madeleine" uniqKey="Duvic M" first="Madeleine" last="Duvic">Madeleine Duvic</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>MD Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University Hospital Zurich, Department of Dermatology</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
</affiliation>
</author>
<author><name sortKey="Becker, Jurgen C" sort="Becker, Jurgen C" uniqKey="Becker J" first="Jürgen C." last="Becker">Jürgen C. Becker</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Medical University of Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Poulalhon, Nicolas" sort="Poulalhon, Nicolas" uniqKey="Poulalhon N" first="Nicolas" last="Poulalhon">Nicolas Poulalhon</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Centre Hospitalier Lyon Sud</s1>
<s2>Pierre-Bénite</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ortiz Romero, Pablo" sort="Ortiz Romero, Pablo" uniqKey="Ortiz Romero P" first="Pablo" last="Ortiz Romero">Pablo Ortiz Romero</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Instituto i+12 del Hospital 12 de Octubre, Facultad de Medicina, Universidad Complutense</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Grazia Bernengo, Maria" sort="Grazia Bernengo, Maria" uniqKey="Grazia Bernengo M" first="Maria" last="Grazia Bernengo">Maria Grazia Bernengo</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University of Turin, Department of Biomedical Science and Human Oncology</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbe">Celeste Lebbe</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>AP-HP Hôpital Saint-Louis, Department of Dermatology and Center of Clinical Investigation, Université Paris Diderot</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Assaf, Chalid" sort="Assaf, Chalid" uniqKey="Assaf C" first="Chalid" last="Assaf">Chalid Assaf</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>HELIOS Klinikum Krefeld, Department of Dermatology</s1>
<s2>Krefeld</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Skin Cancer Center Charité, Department of Dermatology and Allergology, Charité-Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Squier, Margaret" sort="Squier, Margaret" uniqKey="Squier M" first="Margaret" last="Squier">Margaret Squier</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, NJ</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Williams, Denise" sort="Williams, Denise" uniqKey="Williams D" first="Denise" last="Williams">Denise Williams</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, NJ</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Marshood, Miriam" sort="Marshood, Miriam" uniqKey="Marshood M" first="Miriam" last="Marshood">Miriam Marshood</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, NJ</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Feng Tai" sort="Feng Tai" uniqKey="Feng Tai" last="Feng Tai">FENG TAI</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, NJ</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Prince, H Miles" sort="Prince, H Miles" uniqKey="Prince H" first="H. Miles" last="Prince">H. Miles Prince</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Peter MacCallum Cancer Centre and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0084490</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0084490 INIST</idno>
<idno type="RBID">Pascal:13-0084490</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C21</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005244</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial</title>
<author><name sortKey="Duvic, Madeleine" sort="Duvic, Madeleine" uniqKey="Duvic M" first="Madeleine" last="Duvic">Madeleine Duvic</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>MD Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University Hospital Zurich, Department of Dermatology</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
</affiliation>
</author>
<author><name sortKey="Becker, Jurgen C" sort="Becker, Jurgen C" uniqKey="Becker J" first="Jürgen C." last="Becker">Jürgen C. Becker</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Medical University of Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Poulalhon, Nicolas" sort="Poulalhon, Nicolas" uniqKey="Poulalhon N" first="Nicolas" last="Poulalhon">Nicolas Poulalhon</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Centre Hospitalier Lyon Sud</s1>
<s2>Pierre-Bénite</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ortiz Romero, Pablo" sort="Ortiz Romero, Pablo" uniqKey="Ortiz Romero P" first="Pablo" last="Ortiz Romero">Pablo Ortiz Romero</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Instituto i+12 del Hospital 12 de Octubre, Facultad de Medicina, Universidad Complutense</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Grazia Bernengo, Maria" sort="Grazia Bernengo, Maria" uniqKey="Grazia Bernengo M" first="Maria" last="Grazia Bernengo">Maria Grazia Bernengo</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University of Turin, Department of Biomedical Science and Human Oncology</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbe">Celeste Lebbe</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>AP-HP Hôpital Saint-Louis, Department of Dermatology and Center of Clinical Investigation, Université Paris Diderot</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Assaf, Chalid" sort="Assaf, Chalid" uniqKey="Assaf C" first="Chalid" last="Assaf">Chalid Assaf</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>HELIOS Klinikum Krefeld, Department of Dermatology</s1>
<s2>Krefeld</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Skin Cancer Center Charité, Department of Dermatology and Allergology, Charité-Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Squier, Margaret" sort="Squier, Margaret" uniqKey="Squier M" first="Margaret" last="Squier">Margaret Squier</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, NJ</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Williams, Denise" sort="Williams, Denise" uniqKey="Williams D" first="Denise" last="Williams">Denise Williams</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, NJ</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Marshood, Miriam" sort="Marshood, Miriam" uniqKey="Marshood M" first="Miriam" last="Marshood">Miriam Marshood</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, NJ</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Feng Tai" sort="Feng Tai" uniqKey="Feng Tai" last="Feng Tai">FENG TAI</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, NJ</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Prince, H Miles" sort="Prince, H Miles" uniqKey="Prince H" first="H. Miles" last="Prince">H. Miles Prince</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Peter MacCallum Cancer Centre and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European journal of cancer : (1990)</title>
<title level="j" type="abbreviated">Eur. j. cancer : (1990)</title>
<idno type="ISSN">0959-8049</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European journal of cancer : (1990)</title>
<title level="j" type="abbreviated">Eur. j. cancer : (1990)</title>
<idno type="ISSN">0959-8049</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Bexarotene</term>
<term>Biological activity</term>
<term>Cancerology</term>
<term>Chronic</term>
<term>Cutaneous T cell lymphoma</term>
<term>Human</term>
<term>Lymphoid neoplasm</term>
<term>Mycosis fungoides</term>
<term>Panobinostat</term>
<term>Phase II trial</term>
<term>Sezary syndrome</term>
<term>T cell neoplasm</term>
<term>Treatment resistance</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Panobinostat</term>
<term>Activité biologique</term>
<term>Bexarotène</term>
<term>Mycosis fongoïde</term>
<term>Homme</term>
<term>Résistance traitement</term>
<term>Essai clinique phase II</term>
<term>Cancérologie</term>
<term>Syndrome de Sezary</term>
<term>Anticancéreux</term>
<term>Chronique</term>
<term>Lymphome T cutané</term>
<term>Hémopathie maligne lymphoïde</term>
<term>Hémopathie lymphoïde T</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Panobinostat is a potent, oral pan-deacetylase inhibitor (pan-DACi) that increases the acetylation of proteins involved in multiple oncogenic pathways. Here, panobinostat is studied in bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma (CTCL). Patients and methods: Patients with CTCL subtypes mycosis fungoides and Sézary syndrome who received ≥2 prior systemic therapy regimens received panobinostat (20 mg) three times every week. The primary objective was overall response rate (ORR) as determined by a combined evaluation of skin disease and involvement of lymph node and viscera. Disease progression was defined as an unconfirmed, ≥25% increase in modified Severity Weighted Assessment Tool (mSWAT) compared with nadir. Results: Seventy-nine bexarotene-exposed and 60 bexarotene-naïve patients were enrolled. Reductions in baseline mSWAT scores were observed in 103 patients (74.1%). The ORR was 17.3%) in all patients in the primary analysis (15.2% and 20.0% in the bexarotene-exposed and -naive groups, respectively). The median progression-free survival was 4.2 and 3.7 months in the bexarotene-exposed and -naive groups, respectively. The median duration of response was 5.6 months in the bexarotene-exposed patients and was not reached at data cutoff in the bexarotene-naive patients. Additional responses were observed when less-stringent progression criteria were used. The most common adverse events were thrombocytopenia, diarrhoea, fatigue and nausea. Thrombocytopenia and neutropenia were the only grade 3/4 adverse events in >5% of patients and were manageable. Conclusion: Despite a very conservative definition of disease progression, panobinostat demonstrated activity with a manageable safety profile in bexarotene-exposed and -naïve CTCL patients. ClinicalTrials.gov Identifier: NCT00425555.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0959-8049</s0>
</fA01>
<fA03 i2="1"><s0>Eur. j. cancer : (1990)</s0>
</fA03>
<fA05><s2>49</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DUVIC (Madeleine)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DUMMER (Reinhard)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BECKER (Jürgen C.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>POULALHON (Nicolas)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ORTIZ ROMERO (Pablo)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GRAZIA BERNENGO (Maria)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LEBBE (Celeste)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ASSAF (Chalid)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>SQUIER (Margaret)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>WILLIAMS (Denise)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>MARSHOOD (Miriam)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>FENG TAI</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>PRINCE (H. Miles)</s1>
</fA11>
<fA14 i1="01"><s1>MD Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>University Hospital Zurich, Department of Dermatology</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Medical University of Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Centre Hospitalier Lyon Sud</s1>
<s2>Pierre-Bénite</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Instituto i+12 del Hospital 12 de Octubre, Facultad de Medicina, Universidad Complutense</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>University of Turin, Department of Biomedical Science and Human Oncology</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>AP-HP Hôpital Saint-Louis, Department of Dermatology and Center of Clinical Investigation, Université Paris Diderot</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>HELIOS Klinikum Krefeld, Department of Dermatology</s1>
<s2>Krefeld</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Skin Cancer Center Charité, Department of Dermatology and Allergology, Charité-Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Novartis Pharmaceuticals Corporation</s1>
<s2>East Hanover, NJ</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Peter MacCallum Cancer Centre and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA20><s1>386-394</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>12648</s2>
<s5>354000182501500140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>33 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0084490</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>European journal of cancer : (1990)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Panobinostat is a potent, oral pan-deacetylase inhibitor (pan-DACi) that increases the acetylation of proteins involved in multiple oncogenic pathways. Here, panobinostat is studied in bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma (CTCL). Patients and methods: Patients with CTCL subtypes mycosis fungoides and Sézary syndrome who received ≥2 prior systemic therapy regimens received panobinostat (20 mg) three times every week. The primary objective was overall response rate (ORR) as determined by a combined evaluation of skin disease and involvement of lymph node and viscera. Disease progression was defined as an unconfirmed, ≥25% increase in modified Severity Weighted Assessment Tool (mSWAT) compared with nadir. Results: Seventy-nine bexarotene-exposed and 60 bexarotene-naïve patients were enrolled. Reductions in baseline mSWAT scores were observed in 103 patients (74.1%). The ORR was 17.3%) in all patients in the primary analysis (15.2% and 20.0% in the bexarotene-exposed and -naive groups, respectively). The median progression-free survival was 4.2 and 3.7 months in the bexarotene-exposed and -naive groups, respectively. The median duration of response was 5.6 months in the bexarotene-exposed patients and was not reached at data cutoff in the bexarotene-naive patients. Additional responses were observed when less-stringent progression criteria were used. The most common adverse events were thrombocytopenia, diarrhoea, fatigue and nausea. Thrombocytopenia and neutropenia were the only grade 3/4 adverse events in >5% of patients and were manageable. Conclusion: Despite a very conservative definition of disease progression, panobinostat demonstrated activity with a manageable safety profile in bexarotene-exposed and -naïve CTCL patients. ClinicalTrials.gov Identifier: NCT00425555.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Panobinostat</s0>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Panobinostat</s0>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Panobinostat</s0>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Activité biologique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Biological activity</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Actividad biológica</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Bexarotène</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Bexarotene</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Bexaroteno</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Mycosis fongoïde</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Mycosis fungoides</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Micosis fungoides</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Résistance traitement</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment resistance</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Resistencia tratamiento</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Essai clinique phase II</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Phase II trial</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Ensayo clínico fase II</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Syndrome de Sezary</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Sezary syndrome</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Sezary síndrome</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>25</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>25</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>25</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Chronique</s0>
<s5>26</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Chronic</s0>
<s5>26</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Crónico</s0>
<s5>26</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Lymphome T cutané</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Cutaneous T cell lymphoma</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Linfoma T cutáneo</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Hémopathie maligne lymphoïde</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Lymphoid neoplasm</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Hémopathie lymphoïde T</s0>
<s4>CD</s4>
<s5>98</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>T cell neoplasm</s0>
<s4>CD</s4>
<s5>98</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Inhibiteur histone deacetylase</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Histone deacetylase inhibitor</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Inhibidor histone deacetylase</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Lymphome non hodgkinien</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Non Hodgkin lymphoma</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Linfoma no Hodgkin</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Syndrome lymphoprolifératif</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de la peau</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Skin disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Piel patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Hématodermie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Cutaneous hematologic disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Hematodermia</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Lymphome périphérique à cellules T</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Peripheral T cell lymphoma</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Linfoma célula T periférica</s0>
<s5>43</s5>
</fC07>
<fN21><s1>056</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005244 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 005244 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:13-0084490
   |texte=   Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri